Quan Capital
- Company typePrivate
- Founded2017
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
Quan Capital firmographics
Firmographics- Name
- Quan Capital
- Legal name
- Quan Capital
- Website
- https://quancapital.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Quan Capital industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro industry
- Sector-Focused Venture Capital (Vertical Specialists)Healthcare & Life Sciences Growth EquityVenture Capital Fund-of-Funds
Keywords
Where Quan Capital is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Quan Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
Revenue model
- Venture capital fund management: Quan Capital generates revenue as a venture capital firm managing healthcare-focused investment funds (e.g., inaugural $150M healthcare fund per 2017 BioCentury coverage), earning recurring management fees on assets under management and performance-based carried interest on successful portfolio exits. Returns are realized via capital gains from IPOs, M&A, and secondary sales of portfolio companies (e.g., ARMO BioSciences acquired by Lilly; Crescendo Biologics licensing deals; Arcellx, NextCure IPOs).
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Quan Capital product offering
Product offeringCore offering
Quan Capital is a healthcare-focused global venture capital firm that deploys capital from its $150M inaugural healthcare fund into early- and growth-stage life sciences companies across China and global markets. The firm invests as lead or co-lead investor across financing rounds (Series A through crossover/pre-IPO), provides company-building support through incubation, board representation, and operational guidance, and facilitates cross-border China-Global partnerships for its portfolio companies.
Product overview
Quan Capital operates as a single unified venture capital platform with a website that integrates three core service pillars (Company Building, Industry Insights & Strategy, and a Global Partnership Network) around a healthcare-focused investment fund (the inaugural $150M Healthcare Fund). These services are operationalized through a public-facing site comprising a Portfolio Directory, a multi-page bilingual News & Press Releases Center (English and Chinese), a Contact presence across Shanghai and San Francisco offices, and a gated Investor Resources Portal that provides authenticated access for investors via username/email login, password reset and a "Join Us" membership option. Together, these offerings support the firm's lifecycle of identifying, incubating, growing and reporting on life-sciences portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Quan Capital Healthcare Fund The firm's flagship healthcare-focused venture capital fund used to deploy capital into early- and growth-stage life sciences companies across China and global markets, including Series A through crossover/pre-IPO rounds.
- Investor Resources Portal
Quantifiable outcome
- Co-led $89M Series B for Pinnacle Medicines (oversubscribed, March 2026)
- +9 more outcomes
Companies that use Quan Capital
Customer profileNamed customers23 records
Segments4 records
Quan Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Quan Capital partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Chugai Pharmaceutical Co., Ltd. (Alebund co-development partner)minorIndirect portfolio relationship: Chugai entered into an option/license agreement with Quan Capital portfolio company Alebund Pharmaceuticals for EOS789 development in hyperphosphatemia, demonstrating Quan's ability to attract global biopharma partners for its portfolio.
- Thermo Fisher Scientific (Innoforce co-development partner)minorIndirect portfolio relationship: Thermo Fisher Scientific partnered with Quan Capital portfolio company Innoforce to establish a biologics and sterile drug manufacturing facility in China.
- OrbiMed (co-investor)coreOrbiMed is a recurring co-investor alongside Quan Capital across multiple portfolio deals including Windward Bio (Series A and crossover lead), Pinnacle Medicines (existing investor), Adicet Bio, Centrexion Therapeutics, Crescendo Biologics, and Tempest Therapeutics. OrbiMed also incubated Pinnacle Medicines.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Quan Capital competitors and assessment
Company assessmentDirect peers
- Qiming Venture Partners: Qiming is a China-headquartered venture firm with one of the largest dedicated healthcare practices in Asia, investing across biotech, medtech and diagnostics from seed to growth. Like Quan, it operates a China-rooted, globally connected model backing portfolio companies that bridge Chinese and international markets.
- OrbiMed: OrbiMed is the world's largest healthcare-dedicated investment firm, investing across the full life sciences capital stack from venture through royalties. It is Quan's most frequent co-investor (Windward Bio, Pinnacle, Centrexion, Crescendo, Tempest, Adicet), making it the closest comparable business model — a specialist healthcare investor writing large checks alongside Quan.
- RA Capital Management: RA Capital is a US-based crossover fund specialist focused on clinical-stage biotech, frequently co-investing with Quan (Windward Bio crossover, Pinnacle Series B). It shares Quan's late-stage clinical and crossover orientation and competes for the same asset class.
- Lilly Asian Ventures (LAV): LAV is a healthcare-only venture firm with deep ties to Eli Lilly and a strong Shanghai presence. As a co-lead on Pinnacle's $89M Series B, it competes with Quan for the same Asian biotech deals while providing strategic pharma partnership optionality.
- Foresite Capital: Foresite Capital is a US healthcare-focused venture and growth firm. It co-led Pinnacle Medicines' Series B alongside Quan, directly competing for late-stage biotech allocations and sharing a similar crossover/venture hybrid model.
- ARCH Venture Partners: ARCH is one of the most established US healthcare VCs, backing breakthrough biotech platforms from inception through IPO. It competes with Quan for premium early-stage biotech allocations and shares the 'company builder' positioning Quan emphasizes.
- Boyu Capital: Boyu is a major Asia-based alternative investment firm with a dedicated healthcare practice investing in biotech and pharma across China and globally. Its scale and healthcare focus put it in direct competition with Quan for China-rooted life sciences deals.
- Lake Bleu Capital: Lake Bleu Capital is a Hong Kong-based healthcare-dedicated investment manager covering both public and private biotech across Greater China. Its healthcare-only mandate and China-Asia focus make it one of the closest pure-play comparables to Quan.
- Atlas Venture: Atlas Venture is a Boston-based biotech-focused venture firm that builds and incubates therapeutic platforms. It shares Quan's 'company builder' philosophy and competes for the same early-stage clinical biotech deal flow.
Broad incumbents
- Hillhouse Capital: Hillhouse is a large Asia-focused investment manager with a healthcare practice spanning biotech, medtech and healthcare services. While broader than Quan's pure-play healthcare focus, it competes for the same Chinese biotech allocations at larger check sizes.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Quan Capital social profiles
Digital presenceQuan Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quan Capital leadership team
Management profileNumber of profiles
Quan Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quan Capital M&A and investment
M&A and investmentM&A
Investments41 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quan Capital
What does Quan Capital do?
Quan Capital is a healthcare-focused global venture capital firm that deploys capital from its $150M inaugural healthcare fund into early- and growth-stage life sciences companies across China and global markets. The firm invests as lead or co-lead investor across financing rounds (Series A through crossover/pre-IPO), provides company-building support through incubation, board representation, and operational guidance, and facilitates cross-border China-Global partnerships for its portfolio companies.
Is Quan Capital a public or private company?
Quan Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Quan Capital founded?
Quan Capital was founded in 2017. It employs 11 to 50 people.
Where is Quan Capital based?
Quan Capital is headquartered in Shanghai, China, in the Asia region.
How does Quan Capital make money?
One revenue line is on record: venture capital fund management.
Who are Quan Capital's main competitors?
Direct peers on record are Qiming Venture Partners, OrbiMed, RA Capital Management, Lilly Asian Ventures (LAV), Foresite Capital, ARCH Venture Partners, Boyu Capital, Lake Bleu Capital and Atlas Venture. Hillhouse Capital is listed as a broad incumbent.
Does Quan Capital have an API?
No public API is recorded for Quan Capital.
What industry is Quan Capital in?
Quan Capital's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 5239 and its SIC code is 6282.